Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441
Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects
Sponsor: Viatris Innovation GmbH
Terminated
Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported
Other Healthy Subjects trials with similar outcome
A PHASE1 clinical study on Healthy Subjects, this trial is terminated or withdrawn. The trial is conducted by Viatris Innovation GmbH and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Aug 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Viatris Innovation GmbH
For direct contact, visit the study record on ClinicalTrials.gov .